The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The United States orthopedic braces and support market is expected to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Orthopedic braces and support are durable medical instruments designed to alleviate chronic pain or temporary discomfort in case of road accidents and sports injuries. They are used to hold, align, correct, or support external body parts while healing from an injury. Orthopedic braces and support are made from specialized materials with intelligent designs that offer intense targeted support to the knees, spine, shoulder, hips, ankle, foot, and other body parts. In the United States, patients prefer orthopedic braces and support as they help safeguard joints after surgery and provide mobility to the patient suffering from musculoskeletal problems.
The United States orthopedic braces and supports market is primarily driven by the sedentary habits and hectic lifestyles of the working population, resulting in the increasing instances of lower back pain among them. The rising geriatric population, which is more susceptible to osteoporosis, osteomalacia, osteogenesis and injuries, is also providing a positive thrust to the market. Along with this, manufacturers are launching new products, which is escalating the demand for braces and supports. For example, Breg Inc. launched a new product called the Ultra Aurora Ankle Brace, which combines the comfort of an ankle cuff with the stability and control of a rigid hinged footplate.
IMARC Group provides an analysis of the key trends in each sub-segment of the United States orthopedic braces and support market, along with forecasts at the country and regional level from 2021-2026. Our report has categorized the market based on product, type, application and end user.
Breakup by Product:
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Type, Application, End User, Region|
|Region Covered||Northeast, Midwest, South, West|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 2999
Corporate License: US$ 3999
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at